Harousseau, Jean-Luc <br/><br/>
Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Oct 2010 
 - 4621-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2009.27.9158  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Boronic Acids--administration & dosage<br/>Bortezomib<br/>Chemotherapy, Adjuvant<br/>Chi-Square Distribution<br/>Dexamethasone--administration & dosage<br/>Disease-Free Survival<br/>Doxorubicin--administration & dosage<br/>Europe<br/>Female<br/>Humans<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Multiple Myeloma--diagnosis<br/>Neoadjuvant Therapy<br/>Neoplasm Staging<br/>Protease Inhibitors--administration & dosage<br/>Pyrazines--administration & dosage<br/>Stem Cell Transplantation<br/>Time Factors<br/>Transplantation, Autologous<br/>Treatment Outcome<br/>Vincristine--administration & dosage